Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Participants diagnosed with Type 1 or Type 2 diabetes at least one year prior to the screening visit (Week -3).~* Signed written informed consent~* Participants with type 1 or type 2 diabetes treated with insulin whose LDL-C levels were not adequately controlled with maximally tolerated lipid-modifying therapy~* LDL-C of 70 mg/dL or greater~* 18 years of age or more~* Glycosylated hemoglobin (HbA1c) less than 10%~* History of cardiovascular disease (including coronary heart disease \[CHD\] and/or CHD risk equivalents) and/or at least one additional cardiovascular risk factor~Exclusion criteria:~* Not on a stable dose of statin or other lipid modifying therapy for at least 4 weeks prior to screening or from screening to randomization, unless statin intolerant~* Triglycerides \>400 mg/dL~* Estimated glomerular filtration rate (eGFR) \<15 mL/min/1.73 m² according to the Modification of Diet in Renal Disease (MDRD) equation~* Currently received or planned to receive renal replacement therapy (for example, hemodialysis)~* Change in weight of more than 5 kilograms within the prior 2 months~* Not on a stable dose/regimen of insulin or other antidiabetic drugs for the past 3 months or planned to intensify insulin regimen during the study~* Not treated with insulin for at least 6 months~* Planned to start new lipid modifying therapy or change dose of current lipid modifying therapy during the study~* Body mass index (BMI) \>45 kg/m² or planned to undergo bariatric surgery, weight loss program, or initiate weight loss drugs during the study~* History of recent decompensation of diabetes within the prior 2 months (for example, diabetic ketoacidosis)~The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Alirocumab 75 mg Q2W/Up to 150 mg Q2W (Type: EXPERIMENTAL): Alirocumab 75 mg subcutaneous (SC) injection every 2 weeks (Q2W) added to stable, maximally tolerated dose of statin therapy with or without other lipid-modifying therapy (LMT), insulin alone or with other antihyperglycemic drugs for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when LDL-C levels ≥70 mg/dL (1.81 mmol/L) at Week 8.
- Placebo Q2W (Type: PLACEBO_COMPARATOR): Placebo (for alirocumab) SC injection Q2W added to stable, maximally tolerated dose of statin therapy with or without other LMT, insulin alone or with other antihyperglycemic drugs for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).